EcoDrugPlus

Protein Kinase D1

Ensembl ID : ENSPFOG00000010961
Gene Symbol: PRKD1
3 Cross references
204 Possible Orthologues:

Protein Kinase D3

Ensembl ID : ENSPFOG00000003286
Gene Symbol: PRKD3
3 Cross references
209 Possible Orthologues:

Protein Kinase, Dna-Activated, Catalytic Subunit

Ensembl ID : ENSPFOG00000009853
Gene Symbol: PRKDC
3 Cross references
184 Possible Orthologues:

Protein Phosphatase 3 Catalytic Subunit Alpha

Ensembl ID : ENSPFOG00000000045
Gene Symbol: PPP3CA
4 Cross references
233 Possible Orthologues:

Protein Tyrosine Kinase 2

Ensembl ID : ENSPFOG00000003397
Gene Symbol: PTK2
1 Cross references
246 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11

Ensembl ID : ENSPFOG00000009691
Gene Symbol: PTPN11
3 Cross references
251 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSPFOG00000005803
Gene Symbol: PTPRB
2 Cross references
203 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSPFOG00000010470
Gene Symbol: PTPRB
2 Cross references
189 Possible Orthologues:

Protein-Serine O-Palmitoleoyltransferase Porcupine-Like

Ensembl ID : ENSPFOG00000017013
Gene Symbol: LOC103154223
3 Cross references
197 Possible Orthologues:

Protein-Tyrosine Kinase 2-Beta-Like

Ensembl ID : ENSPFOG00000008438
Gene Symbol: LOC103138634
3 Cross references
195 Possible Orthologues:

Protein-Tyrosine Kinase 6-Like

Ensembl ID : ENSPFOG00000011705
Gene Symbol: LOC103148180
3 Cross references
157 Possible Orthologues:

Proteinase-Activated Receptor 1-Like

Ensembl ID : ENSPFOG00000009051
Gene Symbol: LOC103135850
3 Cross references
263 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).